Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O00506
UPID:
STK25_HUMAN
Alternative names:
Ste20-like kinase; Sterile 20/oxidant stress-response kinase 1
Alternative UPACC:
O00506; A8K6Z3; A8K7D2; B7Z9K1; Q15522; Q5BJF1
Background:
Serine/threonine-protein kinase 25, also known as Ste20-like kinase and Sterile 20/oxidant stress-response kinase 1, is a crucial enzyme in cellular response to environmental stress. It primarily activates in response to oxidant stress, targeting the Golgi apparatus to regulate protein transport, cell adhesion, and polarity complexes, which are vital for cell migration.
Therapeutic significance:
Understanding the role of Serine/threonine-protein kinase 25 could open doors to potential therapeutic strategies.